KemPharm is engaged in the discovery and development of proprietary prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
KemPharm’s intent is to develop prodrugs that have improved properties over approved drugs and address unmet medical needs in large, established markets.more »
LAT™ Prodrug Pipeline
KemPharm’s strategy is to leverage its LAT™ (Ligand Activated Therapy) prodrug discovery platform to create a portfolio of product candidates that offer improvements over FDA-approved and widely prescribed drugs. KemPharm’s pipeline consist of multiple programs targeting opportunities in pain, ADHD and CNS indications.more »